The use of bispecific T cell engagers (also known as BiTE) therapies has been increasing to treat patients with blood cancers. However, there are side effects and other factors to consider when deciding on the treatment type, explained Kathy Mooney.
Mooney, clinical program director at Johns Hopkins Hospital and Johns Hopkins Health System, sat down with CURE® at the 49th Annual Oncology Nursing Society Congress to discuss BiTE therapies.
“It’s an intense model of care, especially in the beginning. Its frequent dosing [and] there are harsh side effects that the patients need to be aware of,” Mooney said. Common side effects from BiTE therapy include neurotoxicity (nervous system damage) and cytokine release syndrome, when there is an influx of inflammatory molecules, called cytokines, in the bloodstream. Cytokine release syndrome can be serious and life-threatening if it is not caught early on.
READ MORE: Educated Patient® Multiple Myeloma Summit BiTE and Future Myeloma Directions Presentation
“So, ensuring that they have good social support is probably key to the initial step-up dosing,” Mooney said. Social support is important because it can help look for signs of side effects, transportation assistance and communication with doctors.
Step-up dosing means that a small amount of the drug will be administered at first, and the dosage increases as the treatment progresses.
However, for patients who do not have strong social support at home, Mooney said that does not mean the BiTE therapies are out of the question. She advised these patients to be open with their care teams if this is the case. Assistance programs exist, such as those that can help with lodging or transportation. Additionally, for these patients, maybe it is best to receive BiTE therapy in the inpatient (hospital) setting, rather than outpatient (in a clinic outside of the hospital), Mooney said.
Transcript:
It's an intense model of care, especially in the beginning, it's frequent dosing [and] there are harsh side effects that the patients need to be aware of. So ensuring that they have good social support is probably key to the initial step-up dosing. We need to make sure that they are safe, and that they can be transitioned quickly to care areas when they need that and have somebody looking out for them for any of those signs and symptoms that may occur.
Some of these options are also … long treatment. There's no end date for the treatment. So making sure they're aware that this is going to be an intense therapy for many months, many weeks, and making sure they feel comfortable with the ability to continue that care [is important].
For more news on cancer updates, research and education, don’t forget to subscribe to CURE®’s newsletters here.
Social Support Is Key During BiTE Therapy for Blood Cancers
An oncology nurse discusses what patients should know before BiTE therapy, and what they can do if they do not have a social support system.
The use of bispecific T cell engagers (also known as BiTE) therapies has been increasing to treat patients with blood cancers. However, there are side effects and other factors to consider when deciding on the treatment type, explained Kathy Mooney.
Mooney, clinical program director at Johns Hopkins Hospital and Johns Hopkins Health System, sat down with CURE® at the 49th Annual Oncology Nursing Society Congress to discuss BiTE therapies.
“It’s an intense model of care, especially in the beginning. Its frequent dosing [and] there are harsh side effects that the patients need to be aware of,” Mooney said. Common side effects from BiTE therapy include neurotoxicity (nervous system damage) and cytokine release syndrome, when there is an influx of inflammatory molecules, called cytokines, in the bloodstream. Cytokine release syndrome can be serious and life-threatening if it is not caught early on.
READ MORE: Educated Patient® Multiple Myeloma Summit BiTE and Future Myeloma Directions Presentation
“So, ensuring that they have good social support is probably key to the initial step-up dosing,” Mooney said. Social support is important because it can help look for signs of side effects, transportation assistance and communication with doctors.
Step-up dosing means that a small amount of the drug will be administered at first, and the dosage increases as the treatment progresses.
However, for patients who do not have strong social support at home, Mooney said that does not mean the BiTE therapies are out of the question. She advised these patients to be open with their care teams if this is the case. Assistance programs exist, such as those that can help with lodging or transportation. Additionally, for these patients, maybe it is best to receive BiTE therapy in the inpatient (hospital) setting, rather than outpatient (in a clinic outside of the hospital), Mooney said.
Transcript:
It's an intense model of care, especially in the beginning, it's frequent dosing [and] there are harsh side effects that the patients need to be aware of. So ensuring that they have good social support is probably key to the initial step-up dosing. We need to make sure that they are safe, and that they can be transitioned quickly to care areas when they need that and have somebody looking out for them for any of those signs and symptoms that may occur.
Some of these options are also … long treatment. There's no end date for the treatment. So making sure they're aware that this is going to be an intense therapy for many months, many weeks, and making sure they feel comfortable with the ability to continue that care [is important].
For more news on cancer updates, research and education, don’t forget to subscribe to CURE®’s newsletters here.
Cancer and Fatigue Go Together
May 15th 2024As a cancer survivor, I’m pleading for more research on cancer related fatigue.
Read More
Certain Immunotherapy Drugs Not Recommended for Pregnant Women With Cancer
May 10th 2024When possible, immune checkpoint inhibitors should be avoided in pregnant women with cancer due to lung inflammation and possible miscarriage, researchers found.
Read More
Pelabresib Combo Leads to Outcomes Linked to Better Survival in Myelofibrosis
April 16th 2024Pelabresib plus Jakafi led to a reduction in spleen size and was tolerable in patients with myelofibrosis, according to data from MANIFEST-2.
Read More
How COVID-19 Helped Me Cope Day to Day With Cancer
April 11th 2024I was surprised that COVID-19 taught me how to cope with the daily annoyances of cancer.
Read More
Lower Childbirth Rates Shown in Women With MPNs
April 3rd 2024Childbirth rates have been reduced by 22% in women with MPNs, compared with women without MPNs, researchers found.
Read More
FDA Approvals in the Blood Cancer Space from Early 2024
April 1st 2024The Food and Drug Administration approved multiple new therapies for blood cancer over the last few months.
Read More
Cancer and Fatigue Go Together
May 15th 2024As a cancer survivor, I’m pleading for more research on cancer related fatigue.
Read More
Certain Immunotherapy Drugs Not Recommended for Pregnant Women With Cancer
May 10th 2024When possible, immune checkpoint inhibitors should be avoided in pregnant women with cancer due to lung inflammation and possible miscarriage, researchers found.
Read More
Pelabresib Combo Leads to Outcomes Linked to Better Survival in Myelofibrosis
April 16th 2024Pelabresib plus Jakafi led to a reduction in spleen size and was tolerable in patients with myelofibrosis, according to data from MANIFEST-2.
Read More
How COVID-19 Helped Me Cope Day to Day With Cancer
April 11th 2024I was surprised that COVID-19 taught me how to cope with the daily annoyances of cancer.
Read More
Lower Childbirth Rates Shown in Women With MPNs
April 3rd 2024Childbirth rates have been reduced by 22% in women with MPNs, compared with women without MPNs, researchers found.
Read More
FDA Approvals in the Blood Cancer Space from Early 2024
April 1st 2024The Food and Drug Administration approved multiple new therapies for blood cancer over the last few months.
Read More